Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nipah virus vaccine (Phylex BioSciences)
- Development stage
- Preclinical
- Lead developer
- Phylex BioSciences
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
Phylex BioSciences is developing an mRNA-based vaccine for the prevention of Nipah virus infection. The vaccine utilizes a proprietary platform where the messenger RNA encodes an antigen that is displayed on a self-assembling nanoparticle. This technology is designed to enhance the immune response by presenting the antigen in a multivalent, virus-like format. The candidate is currently in preclinical development, with the company pursuing parallel tracks for preclinical-grade and cGMP manufacturing.
- Other names
- Phylex Nipah mRNA vaccine
02
Targets
NiV (Nipah virus)
Beyond the preview
Go deeper on Nipah virus vaccine (Phylex BioSciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nipah virus vaccine (Phylex BioSciences).